Four-year cumulative risk of any relapse lower for dasatinib in the context of intensive chemotherapy.
A Phase 1 trial of dasatinib combined with paclitaxel and carboplatin has determined the optimal dose of dasatinib and suggested some efficacy in women with advanced or recurrent ovarian cancer.
Combining the hyperCVAD regimen with dasatinib, a dual Scr and BCR-ABL kinase inhibitor, is effective in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) or chronic myeloid leukemia in the lymphoid blast phase (CML-LB), according to investigators at the 53rd American Society of Hematology Annual Meeting and Exposition.
The BCR-ABL kinase inhibitor dasatinib achieved significantly higher and faster rates of complete cytogenetic response and major molecular response than imatinib as first-line treatment in patients with previously untreated chronic myeloid leukemia, according to 24-month follow-up results from the randomized Phase 3 DASISION trial reported at the American Society of Clinical Oncology's 2011 Annual Meeting.
Bosutinib has therapeutic potential in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic-phase (CP) chronic myeloid leukemia (CML) with resistance to—or, particularly, intolerance to—other second-generation tyrosine kinase inhibitor (TKI) therapies, results of an open-label, phase 1/2 study presented at the 52nd American Society of Hematology Annual Meeting and Exposition has found.
Both dasatinib (DAS) and imatinib (IM) are highly effective and generally well tolerated in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP), results of an open-label phase 2 study presented at the 52nd American Society of Hematology Annual Meeting and Exposition have found.
Dasatinib continues to demonstrate superior efficacy compared with imatinib as initial treatment for patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP), results of an 18-month follow-up of the phase 3 DASISION comparative trial have shown. The data was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.
Dasatinib 20mg, 50mg, 70mg, 80mg, 100mg, 140mg; tabs.
Drug Monograph Updates
The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of February. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…